Bionano Genomics
Bionano Genomics Upbeat on Further Clinical Adoption of Optical Genome Mapping With New CPT Code
Premium
The Category I CPT code paves the way for reimbursement of OGM-based clinical tests, though details on pricing and insurance coverage are still unclear.
Bionano Genomics Inks OEM Deal With Chinese Partner to Commercialize Clinical Cytogenetics Workflow
Hangzhou Diagens Biotechnology has received China NMPA approval for Bionano's reagents and plans to register the Saphyr instrument for use in reproductive health.
Written by early OGM adopters, the framework describes best practices for the technology's clinical implementation for hematological malignancies.
Top Five Articles on 360Dx Last Week: Bionano Partner Nabs NMPA Approval; Danaher's $5.7B Buy; More
Last week, readers were most interested in a story about Bionano's OEM Partner in China nabbing approval for the firm's DNA extraction and labeling products.
Bionano Genomics' Chinese OEM Partner Nabs NMPA Approval for Sample Prep Products
Through its OEM partner A-smart MedTech, Bionano can now sell two more sample prep products for IVD applications in reproductive health in China.